MicroPort® Toumai® Successfully Performed Difficult Procedures for Registered Multidisciplinary Clinical Trials

Lanzhou, China, 1 November 2021 - Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot) successfully completed two difficult clinical trial surgeries - right lung lower lobe resection and radical resection of distal gastric cancer at Gansu Provincial Hospital recently. These surgeries, performed by Toumai® Laparoscopic Surgery Robot (Toumai®), marked important progress made by this robotic system in clinical application in the field of thoracic surgery and general surgery following its use in urology.

The surgeries were successfully completed by the teams of Prof. Yunjiu Gou, Chief Physician of Thoracic Surgery, and Prof. Yuntao Ma, Chief Physician of General Surgery, of the Hospital. The distal gastric cancer radical surgery was the eighth case of general surgery completed by Prof. Yuntao Ma since the start of the clinical project. The successful integration of domestic ultrasound knife and other energy instruments on MicroPort®’s robotic platform has ensured smooth implementation of robot-assisted general surgeries.

According to Mr. Yu Liu, Chief Commercial Officer of MicroPort® MedBot, “We are very grateful to Prof. Yuntao Ma, Prof. Yunjiu Gou and their teams. While actively fighting against the COVID-19 pandemic, they have also completed multiple procedures for registered clinical trials using MicroPort® Toumai® laparoscopic surgery robots out of their enthusiasm and expectation for development of surgical robots in China. The successful completion of multiple difficult surgical cases with MicroPort® Toumai® fully proves that MicroPort®’s surgical robots can support not only all kinds of pelvic surgeries, but also multi-clinical applications in thoracic and abdominal cavities. We believe that with further launch of more clinical trials and by strengthening our cooperation with more clinical centers, we will accelerate the improvement and maturation of surgical robots in clinical applications, and provide more accurate, intelligent, efficient, and universal medical robot solutions for doctors and patients worldwide."

About Shanghai MicroPort MedBot (Group) Co., Ltd.

MicroPort® MedBot (stock code: 02252.HK) is a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK, MicroPort®). MicroPort® started its strategic development of medical robots in 2014 and has since been engaged in independent research and development of endoscopic surgical robots. Over the years, MicroPort® MedBot has focused on the development and commercialization of minimally invasive and noninvasive surgical robots, with integrated solutions gradually created for multiple clinical applications on five ‘golden tracks’, namely laparoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture.